Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Brain Diseases » Epilepsy
Description
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) MeSH
Hierarchy View
Subtype Terms (8)
Drug Resistant Epilepsy
37 drugs (28 approved, 9 experimental)
Epilepsies, Partial
37 drugs (27 approved, 10 experimental)
Epilepsy, Benign Neonatal
1 approved drug
Epilepsy, Generalized
7 drugs (6 approved, 1 experimental)
Epilepsy, Post-Traumatic
5 drugs (4 approved, 1 experimental)
Epilepsy, Reflex
12 drugs (6 approved, 6 experimental)
Epileptic Syndromes
1 approved drug
Sudden Unexpected Death in Epilepsy
4 approved drugs
Approved Indicated Drugs (29)
Phase 4 Indicated Drugs (23)
Phase 3 Indicated Drugs (21)
Phase 2 Indicated Drugs (41)
Phase 1 Indicated Drugs (18)
Other Experimental Indicated Drugs (17)
Organization Involved with Phase 4 Indications (96)
Azienda Ospedaliera San Gerardo di Monza
California Medical Clinic for Headache
Hoosier Cancer Research Network
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
IRCCS National Neurological Institute C. Mondino Foundation
Lancashire Teaching Hospitals NHS Foundation Trust
National Center for Research Resources (NCRR)
National Institute for Health Research, United Kingdom
National Institute of Mental Health (NIMH)
Northeast Regional Epilepsy Group
NY Harbor VA Healthcare System
Organization Involved with Phase 3 Indications (83)
Ache Laboratorios Farmaceuticos S.A.
Children's National Medical Center
Comprehensive Epilepsy Care Center for Children & Adults
Hospital Santo António Largo, Porto, Portugal
Institut National de la Santé Et de la Recherche Médicale, France
Maharashtra University of Health Sciences
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Psychiatry and Neurology, Budapest, Hungary
Pharmaceutical Research Associates, Inc. (PRA)
Philipps University of Marburg
Scienze Neurologiche Ospedaliere
SMT KASHIBAI NAVALE MEDICAL COLLEGE
The Canadian College of Naturopathic Medicine
Organization Involved with Phase 2 Indications (51)
Icahn School of Medicine at Mount Sinai
Katholieke Universiteit Leuven
National Center for Complementary and Integrative Health (NCCIH)
Organization Involved with Phase 1 Indications (18)
Organization Involved with Other Experimental Indications (30)
Case Western Reserve University
Citizens United for Research in Epilepsy
College of Physicians and Surgeons of Ontario
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
